Concurrent administration of vinorelbine with human recombinant granulocyte-macrocyte stimulating factor
- Authors:
- Published online on: March 1, 2001 https://doi.org/10.3892/ijo.18.3.629
- Pages: 629-632
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Thirty-three patients with incurable neoplasms resistant to standard therapy received vinorelbine 10 mg/m2/day by continuous infusion with concurrent administration of rHGM-CSF 4 μg/m2/day. The duration of the vinorelbine infusion was individualized; the infusion was continued until early evidence of hematopoietic toxicity was noted. The concurrent administration of GM-CSF permitted a substantial increase in dose intensity of the anti-cancer agent without a corresponding increase in drug toxicity. There was no evidence that the anti-tumor effect of vinorelbine was compromised by the concurrent administration of GM-CSF.
